1e
19
1
49
2
2
18
1b
1d
18
35
5c
1d
2 29
1d
25
Beatriz M. Carreno, PhD
78
5c
Research Professor of Pathology and Laboratory Medicine
28
84
3
78
Member, University of Pennsylvania, Parker Institute for Cancer Immunotherapy
73
Member, University of Pennsylvania, Institute for Immunology
7e
Member, University of Pennsylvania, Center for Cellular Immunotherapies
11
Department: Pathology and Laboratory Medicine
4
1
23
1f
Graduate Group Affiliations
8
a
b
1d
46
Contact information
49
4
3
3
1d
49
PCAM South Tower, 8th Floor
32 3400 Civic Blvd
Philadelphia, PA 19104
26
32 3400 Civic Blvd
Philadelphia, PA 19104
2e
Office: 215-573-7044
3e Lab: 215-573-4931
18
85
3e Lab: 215-573-4931
18
Email:
bcarreno@upenn.edu
12
bcarreno@upenn.edu
18
Publications
23 a
3
2
29
23 a
Links
b9 Search PubMed for articles
88 University of Pennsylvania, Center for Cellular Immunotherapies site
c
4
b
1f
b9 Search PubMed for articles
88 University of Pennsylvania, Center for Cellular Immunotherapies site
c
13
Education:
21 7 BS c
46 Universidad Simon Bolivar, Caracas, Venezuela, 1981.
21 8 PhD 19 (Microbiology) c
41 Georgetown University School of Medicine, 1989.
c
3
3
3
3
8d
Permanent link21 7 BS c
46 Universidad Simon Bolivar, Caracas, Venezuela, 1981.
21 8 PhD 19 (Microbiology) c
41 Georgetown University School of Medicine, 1989.
c
2 29
21
1e
1d
24
2b
29
27
23
1b7 Blanchard T., Faridi P., Xu C., Bear A.S., Rasool R.U., Huang G., Lim T.C.C., Ayala R., Gabunia K., Ji M., Posey A.D. Jr, Scholler J., Asangani I.A., Purcell A.W., Linette G.P., June C.H., Carreno B.M.: LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma. Sci Rep 15(1): 13007, Apr 2025 Notes: doi: 10.1038/s41598-025-96877-9. PMID: 40234527 Free PMC article.
291 Porazzi P., Nason S., Yang Z., Carturan A., Ghilardi G., Guruprasad P., Patel R.P., Tan M., Padmanabhan A.A., Lemoine J., Fardella E., Zhang Y., Pajarillo R., Chen L., Ugwuanyi O., Markowitz K., Delman D., Angelos M.G., Shestova O., Isshiki Y., Blanchard T., Béguelin W., Melnick A.M., Linette G.P., Beatty G.L., Carreno B.M., Cohen I.J., Paruzzo L., Schuster S.J., Ruella M.: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell 43(3): 537-551.e7, Mar 2025 Notes: doi: 10.1016/j.ccell.2025.01.013. Epub 2025 Feb 20. PMID: 39983725
213 Bear A.S., Nadler R.B., O'Hara M.H., Stanton K.L., Xu C., Saporito R.J., Rech A.J., Baroja M.L., Blanchard T., Elliott M.H., Ford M.J., Jones R., Patel S., Brennan A., O'Neil Z., Powell D.J. Jr, Vonderheide R.H., Linette G.P., Carreno B.M.: Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest 134(21): e175790, Sep 2024 Notes: doi: 10.1172/JCI175790. PMID: 39287991 Free PMC article. Clinical Trial.
2ec Patel, R.P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K., Chun, I., Angelos, M.G., Pajarillo, R., Hong, S., Lee, Y., Shestova, O., Shaw, C., Cohen, I., Gupta, A., Vu, T., Qian, D., Yang, S., Nimmagadda, A., Snook, A.E., Siciliano, N., Rotolo, A., Inamdar, A., Harris, J., Ugwuanyi, O., Wang, M., Carturan, A., Paruzzo, L., Chen, L., Ballard, H.J., Blanchard, T., Xu, C., Abdel-Mohsen, M., Gabunia, K., Wysocka, M., Linette, G.P., Carreno, B.M., Barrett, D.M., Teachey, D.T., Posey, A.D., Powell Jr., D.J., Sauter, C.T., Pileri, S., Pillai, V., Scholler, J., Rook, A.H., Schuster, S.J., Barta, S.K., Porazzi, P., Ruella, M.: CD5 deletion enhances the antitumor activity of 59 adoptive T cell therapies. Sci Immunol 9(97): eadn6509, Jul 2024.
372 Patel R.P., Ghilardi G., Zhang Y., Chiang Y.H., Xie W., Guruprasad P., Kim K.H., Chun I., Angelos M.G., Pajarillo R., Hong S.J., Lee Y.G., Shestova O., Shaw C., Cohen I., Gupta A., Vu T., Qian D., Yang S., Nimmagadda A., Snook A.E., Siciliano N., Rotolo A., Inamdar A., Harris J., Ugwuanyi O., Wang M., Carturan A., Paruzzo L., Chen L., Ballard H.J., Blanchard T., Xu C., Abdel-Mohsen M., Gabunia K., Wysocka M., Linette G.P., Carreno B.M., Barrett D.M., Teachey D.T., Posey A.D., Powell D.J. Jr, Sauter C.T., Pileri S., Pillai V., Scholler J., Rook A.H., Schuster S.J., Barta S.K., Porazzi P., Ruella M.: CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci Immunol 9(97): eadn6509, Jul 2024 Notes: doi: 10.1126/sciimmunol.adn6509. Epub 2024 Jul 19. PMID: 39028827 Free PMC article.
120 Linette GP, Bear AS, Carreno BM: Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations. Clin Cancer Res Jan 2024 Notes: doi: 10.1158/1078-0432.CCR-23-1212. Online ahead of print.
160 Lee IK, Sharma N, Noguera-Ortega E, Liousia M, Baroja ML, Etersque JM, Pham J, Sarkar S, Carreno BM, Linette GP, Puré E, Albelda SM, Sellmyer MA.: A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy. Mol Ther 31(12): 3564-3578, Dec 2023.
2a8 Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA.: Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood Cancer Discov 4(2): 118-133, Mar 2023.
16d Bear, A.S., Nadler, R.B., Scholler, J., Vonderheide, R.H., Linette, G.P., Carreno, B.M.: TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development. AACR- Targeting Ras, Philadelphia, PA Mar 2023 Notes: Oral Presentation.
2c
7
1d
1f
Selected Publications
1a5 Benton A., Liu J., Poussin M.A., Lang Goldgewicht A., Udawela M., Bear A.S., Wellhausen N., Carreno B.M., Smith P.M., Beasley M.D., Kiefel B.R., Powell D.J. Jr: Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. Cancer Cell 43(7): 1365-1376.e5, Jul 2025 Notes: doi: 10.1016/j.ccell.2025.05.006. Epub 2025 Jun 5. PMID: 404802321b7 Blanchard T., Faridi P., Xu C., Bear A.S., Rasool R.U., Huang G., Lim T.C.C., Ayala R., Gabunia K., Ji M., Posey A.D. Jr, Scholler J., Asangani I.A., Purcell A.W., Linette G.P., June C.H., Carreno B.M.: LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma. Sci Rep 15(1): 13007, Apr 2025 Notes: doi: 10.1038/s41598-025-96877-9. PMID: 40234527 Free PMC article.
291 Porazzi P., Nason S., Yang Z., Carturan A., Ghilardi G., Guruprasad P., Patel R.P., Tan M., Padmanabhan A.A., Lemoine J., Fardella E., Zhang Y., Pajarillo R., Chen L., Ugwuanyi O., Markowitz K., Delman D., Angelos M.G., Shestova O., Isshiki Y., Blanchard T., Béguelin W., Melnick A.M., Linette G.P., Beatty G.L., Carreno B.M., Cohen I.J., Paruzzo L., Schuster S.J., Ruella M.: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell 43(3): 537-551.e7, Mar 2025 Notes: doi: 10.1016/j.ccell.2025.01.013. Epub 2025 Feb 20. PMID: 39983725
213 Bear A.S., Nadler R.B., O'Hara M.H., Stanton K.L., Xu C., Saporito R.J., Rech A.J., Baroja M.L., Blanchard T., Elliott M.H., Ford M.J., Jones R., Patel S., Brennan A., O'Neil Z., Powell D.J. Jr, Vonderheide R.H., Linette G.P., Carreno B.M.: Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest 134(21): e175790, Sep 2024 Notes: doi: 10.1172/JCI175790. PMID: 39287991 Free PMC article. Clinical Trial.
2ec Patel, R.P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K., Chun, I., Angelos, M.G., Pajarillo, R., Hong, S., Lee, Y., Shestova, O., Shaw, C., Cohen, I., Gupta, A., Vu, T., Qian, D., Yang, S., Nimmagadda, A., Snook, A.E., Siciliano, N., Rotolo, A., Inamdar, A., Harris, J., Ugwuanyi, O., Wang, M., Carturan, A., Paruzzo, L., Chen, L., Ballard, H.J., Blanchard, T., Xu, C., Abdel-Mohsen, M., Gabunia, K., Wysocka, M., Linette, G.P., Carreno, B.M., Barrett, D.M., Teachey, D.T., Posey, A.D., Powell Jr., D.J., Sauter, C.T., Pileri, S., Pillai, V., Scholler, J., Rook, A.H., Schuster, S.J., Barta, S.K., Porazzi, P., Ruella, M.: CD5 deletion enhances the antitumor activity of 59 adoptive T cell therapies. Sci Immunol 9(97): eadn6509, Jul 2024.
372 Patel R.P., Ghilardi G., Zhang Y., Chiang Y.H., Xie W., Guruprasad P., Kim K.H., Chun I., Angelos M.G., Pajarillo R., Hong S.J., Lee Y.G., Shestova O., Shaw C., Cohen I., Gupta A., Vu T., Qian D., Yang S., Nimmagadda A., Snook A.E., Siciliano N., Rotolo A., Inamdar A., Harris J., Ugwuanyi O., Wang M., Carturan A., Paruzzo L., Chen L., Ballard H.J., Blanchard T., Xu C., Abdel-Mohsen M., Gabunia K., Wysocka M., Linette G.P., Carreno B.M., Barrett D.M., Teachey D.T., Posey A.D., Powell D.J. Jr, Sauter C.T., Pileri S., Pillai V., Scholler J., Rook A.H., Schuster S.J., Barta S.K., Porazzi P., Ruella M.: CD5 deletion enhances the antitumor activity of adoptive T cell therapies. Sci Immunol 9(97): eadn6509, Jul 2024 Notes: doi: 10.1126/sciimmunol.adn6509. Epub 2024 Jul 19. PMID: 39028827 Free PMC article.
120 Linette GP, Bear AS, Carreno BM: Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations. Clin Cancer Res Jan 2024 Notes: doi: 10.1158/1078-0432.CCR-23-1212. Online ahead of print.
160 Lee IK, Sharma N, Noguera-Ortega E, Liousia M, Baroja ML, Etersque JM, Pham J, Sarkar S, Carreno BM, Linette GP, Puré E, Albelda SM, Sellmyer MA.: A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy. Mol Ther 31(12): 3564-3578, Dec 2023.
2a8 Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA.: Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood Cancer Discov 4(2): 118-133, Mar 2023.
16d Bear, A.S., Nadler, R.B., Scholler, J., Vonderheide, R.H., Linette, G.P., Carreno, B.M.: TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development. AACR- Targeting Ras, Philadelphia, PA Mar 2023 Notes: Oral Presentation.
2c